Aelie

Quick links to important sections

Aelie

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aelie

Property Description
Active ingredient Drospirenone, Ethinylestradiol
Form Oral tablet (monophasic)
Pharmacological class Combined hormonal contraceptive (Estrogen-progestin combination)
Common use Prevention of pregnancy (Contraception)
Origin Synthetic hormones

Identity and Classification of Aelie: A Combined Hormonal Entity

Aelie is a prescription-only pharmaceutical preparation classified as a combined hormonal contraceptive (COC), delivered in an oral tablet form. This combined entity belongs to the therapeutic class of Estrogen-progestin combinations, a category of medications used for systemic administration to achieve temporary fertility control in women of reproductive potential. As a hormonal product, Aelie is clinically recognized for providing highly reliable contraception when used as prescribed.

Composition: The Synthetic Hormones Drospirenone and Ethinylestradiol

Drospirenone and Ethinylestradiol are the two active components that define Aelie, both being chemically synthesized steroid hormones confirming the drug's synthetic origin. Ethinylestradiol serves as the estrogen component, while Drospirenone is a distinctive fourth-generation progestin. This specific progestin component is highlighted for possessing antimineralocorticoid and antiandrogenic activity, properties that differentiate it from many older progestin formulations. Aelie is formulated as a monophasic tablet, which ensures the dose of both active ingredients remains fixed and consistent across the entire active phase of the cycle.

The Primary Purpose of Aelie

The primary purpose of Aelie is the highly effective prevention of pregnancy (contraception). This general use scenario involves providing a dependable, reversible method of family planning. The combination of active ingredients works together to suppress the biological processes necessary for fertility. Combined oral contraceptives are established for this purpose. The overarching benefit is offering a medically confirmed, temporary form of fertility control.

Regulatory References

  1. Birth control pills - combination: MedlinePlus Medical Encyclopedia

What side effects are possible with Aelie?

The official safety profile for Aelie (Drospirenone/Ethinylestradiol) is based strictly on classifications documented in governmental regulatory labeling, outlining potential adverse reactions by frequency and physiological system.

Frequency-Classified Adverse Reactions

Adverse reactions are ranked by their statistical likelihood observed in clinical trials:

  • Very Common (e.g., ge 10%): Includes headache, breast pain or discomfort, and menstrual irregularities such as spotting or breakthrough bleeding.
  • Common (1% to 10%): Reactions include nausea, migraine, depressive mood, emotional lability, fatigue, abdominal pain, and weight gain.
  • Rare (< 0.1%): Includes serious events such as venous and arterial thromboembolism (VTE/ATE).

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight rare but clinically critical risks, primarily involving Vascular Disorders. These include Venous and Arterial Thromboembolism (e.g., Deep Vein Thrombosis, Pulmonary Embolism, Stroke, and Myocardial Infarction). The risk of thromboembolism is officially noted as highest during the first year of use.

Due to the anti-mineralocorticoid activity of Drospirenone, a specific risk of Hyperkalemia (high potassium levels) is documented. Consequently, the medication is contraindicated in individuals with severe renal impairment, adrenal insufficiency, or active liver disease. The label also specifies that use is constrained in women over age 35 who smoke due to significantly increased cardiovascular risks.

Safety is also classified by System-Organ Class, grouping effects on the Nervous System (headache, migraine), Gastrointestinal Disorders (nausea, vomiting), and Psychiatric Disorders (mood changes). Unscheduled bleeding is noted as particularly common during the first three months of use.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This section details the officially documented manifestations of overdosage with Aelie (Drospirenone/Ethinylestradiol) and the required emergency actions, based strictly on government regulatory documents.

Documented Overdose Presentations

Overdosage with combined hormonal contraceptives is primarily associated with non-severe, self-limiting clinical signs. The symptoms documented in regulatory labeling include:

  • Nausea and Vomiting (Gastrointestinal effects)
  • Vaginal Bleeding (Withdrawal bleeding, including in prepubescent females)

Required Emergency Actions and Monitoring

Due to the specific activity of the Drospirenone component, overdosage poses a distinct risk of severe metabolic imbalance, necessitating immediate professional assessment. The official instructions are as follows:

  1. Seek Immediate Medical Attention: Users must immediately seek emergency medical attention or contact a poison control center (or equivalent emergency service) in the event of an overdose.
  2. Specific Monitoring: Though there is no specific antidote, official management requires the monitoring of serum potassium and sodium to detect and manage the risk of hyperkalemia and metabolic acidosis.
  3. Population Risk: This monitoring is especially critical for patients with pre-existing conditions, including renal, hepatic, or adrenal insufficiency, who face a higher risk of developing severe hyperkalemia after an overdose.

Note: Symptomatic treatment is generally provided to address any manifested symptoms.

Therapeutic Uses of Aelie

Aelie (Drospirenone/Ethinylestradiol) is commonly used to help manage symptoms related to physical discomfort and to support functional stability across specific therapeutic areas.

Therapeutic Scope and Symptom Relief

This combination hormonal therapy is primarily applied in the context of family planning and is commonly used to help with fertility control, which represents a primary therapeutic domain. This treatment is relevant across three therapeutic areas, including fertility control, severe cyclical distress (PMDD), and moderate acne vulgaris.

The medication is also used therapeutically to help ease the intense symptomatic burden of Premenstrual Dysphoric Disorder (PMDD). This is relevant for managing symptom clusters that cause noticeable interference with daily comfort, including severe mood swings, anxiety, and cyclical physical symptoms. It offers supportive relief that helps patients cope more steadily with difficult, recurrent episodes of heightened symptoms.

Aelie is considered relevant in clinical settings where patients desire contraception and are dealing with moderate acne vulgaris. This application is applied in addressing the visible manifestations of the skin condition. The benefit contributes to improved day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Cyclical Discomfort The treatment supports the management of menstrual fluctuations, including pronounced pain and heavy bleeding, and is applied in scenarios where additional management of discomfort is required.

Regulatory References

  1. NIH DailyMed / FDA Label

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Aelie

Aelie (Drospirenone/Ethinylestradiol) is intended only for women of reproductive potential who require contraception. Its use is conditionally approved for the treatment of moderate acne vulgaris or Premenstrual Dysphoric Disorder (PMDD), provided the patient also desires an oral contraceptive.


Eligibility Status Defined Population Constraints
Populations Contraindicated Females with a history of or current venous or arterial thromboembolism (VTE/ATE), or those with an inherited or acquired hypercoagulopathy. Those with a history of breast cancer or other hormone-sensitive malignancy are also prohibited from use.
Condition-Specific Restrictions Contraindicated in females with renal impairment, adrenal insufficiency, active liver disease or liver tumors. Also prohibited in cases of uncontrolled hypertension or diabetes mellitus with vascular disease.
Age and Reproductive Status Use is contraindicated before the onset of menstruation (menarche). Females who smoke and are over 35 years of age must not use this medicine. Aelie is contraindicated in pregnancy and not recommended during lactation.
Use Not Established The medicine is not indicated and safety/efficacy are not established in the geriatric (postmenopausal) population.

Official Eligibility Statements: Official regulatory documents establish strict boundaries for Aelie use, primarily to mitigate the risk of serious cardiovascular events. The medicine is contraindicated when pre-existing conditions or risk factors, such as thrombotic disease or uncontrolled hypertension, are present, directly determining who is prohibited from using the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations

Co-administration of Aelie is formally prohibited with certain medicines due to the risk of severe interaction. This includes Hepatitis C drug combinations containing Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir, which are associated with the potential for significant liver enzyme elevation. Co-administration with Fezolinetant and oral Tranexamic Acid is also contraindicated.

Pharmacokinetic and Exposure Interactions

Interactions that alter the hormone exposure of Aelie occur primarily through the Cytochrome P450 system. Strong CYP3A4 inhibitors (such as certain antifungals and HIV protease inhibitors) can increase the systemic exposure of the Drospirenone component. Conversely, CYP3A4 inducers (such as Phenytoin and Rifampin) and the herbal product St. John's wort can decrease the effectiveness of the hormonal components, necessitating the use of an alternative or back-up method.

Pharmacodynamic and Population Constraints

Drospirenone possesses anti-mineralocorticoid activity, which introduces a documented risk of hyperkalemia when co-administered with other agents that increase serum potassium, including Potassium-Sparing Diuretics and ACE Inhibitors. For females at high risk for hyperkalemia, regulatory documents advise monitoring serum potassium during the initial cycle of treatment. Furthermore, the use of Aelie is formally contraindicated in females with Adrenal Insufficiency, Renal Impairment, and Hepatic Impairment.

Mechanism of Action

How Aelie Blocks Calcium Channels and Widens Blood Vessels

Aelie functions as a selective inhibitor of Voltage-Dependent L-type Ca^2+ Channels (VDCC) located on the vascular smooth muscle cell membranes. By binding to these channels, Aelie blocks the influx of extracellular calcium ions ( Ca^2+) required for muscle contraction. This molecular event directly promotes the relaxation of arterial smooth muscle, a process known as vasodilation, which reduces peripheral resistance to blood flow.

Modulating Sympathetic Nervous System Activity

Its action includes suppressing sympathetic nerve activity directed at the vasculature. This reduces the neural drive that typically causes vessel constriction and heart rate acceleration. This modification of sympathetic activity results in a stable or decreased heart rate rather than a compensatory increase.

Systemic Resistance Modulation and Auxiliary Endothelial Effects

The dual mechanistic cascade—vasodilation paired with sympathetic suppression—leads to a controlled, sustained reduction in peripheral vascular resistance. Furthermore, Aelie exhibits auxiliary antioxidant properties within the vessel walls, affecting endothelial function.

Dosage and Administration Information

How to Use Aelie

Aelie is administered via the oral route as a fixed-dose daily tablet. The standard dosage for all approved uses—including contraception, Premenstrual Dysphoric Disorder, and moderate acne vulgaris—is one tablet per day. This dosage does not require titration or adjustment in healthy individuals. The medicine is taken without regard to meals, although it may be advised to take the tablet at the same time every day, preferably after the evening meal or at bedtime, to establish a consistent administration routine.


Administration Protocol and Cycle

Aelie follows a 28-day cyclic regimen designed for continuous, long-term use. This fixed schedule consists of 24 consecutive days of active hormone-containing tablets (3 mg Drospirenone / 0.02 mg Ethinyl Estradiol), immediately followed by 4 consecutive days of inert tablets. Users must take the tablets in the precise order directed on the blister pack, ensuring the 28-day cycle is followed without a tablet-free interval between packs.


Procedural Constraints and Special Conditions

Condition Official Usage Principle
Starting the First Cycle A non-hormonal back-up method must be used for the first seven consecutive days of the initial cycle, unless administration begins on Day 1 of the menstrual period.
Missed Active Dose Specific procedural instructions apply, requiring professional guidance, as the action needed depends on the number of tablets missed and the week of the cycle in which they are missed.
Vomiting/Diarrhea If vomiting or severe diarrhea occurs within 3 to 4 hours of taking an active tablet, the administration is considered a missed dose, and a replacement tablet should be taken.
Population Exclusion The medicine is not indicated for use in the post-menopausal population or in patients with severe hepatic or renal impairment.

These standardized instructions define the required method of intake and the continuous cyclic pattern necessary for the proper use of Aelie.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aelie

Evidence for Use in Pregnancy Prevention (Contraception)

Research exploring the use of Aelie for contraception primarily involves large-scale clinical trials and long-term observational studies. These studies were designed to monitor the consistency of the method in generally healthy women of reproductive age. The studies employed specific metrics, such as the Pearl Index, to calculate and track cumulative pregnancy rates over defined observation periods. Researchers consistently reported patterns of ovarian activity suppression, which is the process studied for its relevance to fertility control.

Evidence for Use in Premenstrual Dysphoric Disorder (PMDD)

This medication was studied for conditions associated with severe cyclical mood and physical symptoms of Premenstrual Dysphoric Disorder (PMDD). Research examined this application through Randomized, Double-Blind, Placebo-Controlled Trials (RCTs), where participants received either the active medication or an inactive comparator. Studies monitored changes in outcomes related to physical discomfort and daily functioning using validated rating scales. Trials reported changes in symptom severity over the observation intervals, but also noted that the comparator group experienced a substantial response.

Evidence for Use in Moderate Acne Vulgaris

Research explored the application for moderate facial acne vulgaris in controlled clinical trials involving female patients who desired hormonal contraception. These studies observed responses over defined time intervals, primarily measuring outcomes linked to inflammatory states of the skin. Studies monitored changes in skin appearance, with findings indicating patterns related to lesion reduction over the course of approximately six treatment cycles.

Areas of Research Uncertainty and Gaps

A major limitation noted across the evidence landscape is that the results apply only to the specific populations studied, and findings describe group patterns rather than individual predictions. Follow-up durations were limited in the symptom-focused trials (PMDD and acne), and long-term effects are not fully established, particularly regarding the maintenance of symptom relief over many years. This evidence highlights what is known—and what is still uncertain.

Key Studies & References Yaz (Drospirenone and Ethinyl Estradiol) Tablets. Prescribing Information.

Frequently Asked Questions (FAQ)

Common questions about Aelie (FAQ)


Q: Can Aelie be taken for long periods of time?

Official documents note that research has investigated the use of this drug combination for periods up to two years. Studies over this timeframe reported a generally comparable safety profile. The duration of use is typically determined by the individual's needs and may involve a regular review.


Q: Are there any long-term effects associated with Aelie use?

Long-term effects continue to be the subject of research. Official information states that long-term safety is not fully established, particularly concerning the maintenance of symptom relief over many years. The drug’s safety profile focuses on potential risks documented during clinical trials.


Q: What is the difference between Aelie and other medicines used for the same purpose?

The official product information notes that the Drospirenone component is unique from some older progestins due to its anti-mineralocorticoid and anti-androgenic properties. These properties are described as differentiating this specific drug combination from certain other hormonal contraceptives.


Q: Are there any common foods or drinks that should be avoided when taking Aelie?

According to official prescribing information, grapefruit and grapefruit juice may need to be avoided. This is due to the potential for these products to interfere with how the medicine is processed in the body.


Q: Can vitamins or supplements interact with Aelie?

Regulatory documents specify that certain herbal products, such as St. John's wort, are known to decrease the medicine’s effectiveness. Additionally, the Ethinyl Estradiol component may increase the blood levels of caffeine.


Q: How does the effectiveness of Aelie compare between different age groups?

Official research evidence primarily focused on generally healthy women of reproductive age. Use of this medication is formally restricted in women over age 35 who smoke, and safety has not been established in the postmenopausal population.


Q: Is there a time limit after a missed dose to still take it?

Official drug documents outline specific and detailed procedural instructions for a missed dose. The required action depends on the number of tablets missed and the week of the cycle, requiring reference to the patient information sheet.


Q: Does Aelie contain any ingredients I might be allergic to?

The active ingredients are Drospirenone and Ethinylestradiol. Official guidance documents require immediate medical attention for symptoms suggesting a severe allergic reaction, such as swelling or rash, which applies to all ingredients, both active and inactive.


Q: Can Aelie affect mental clarity or ability to focus?

Official safety data lists adverse reactions that can affect mood and energy levels. These documented effects include fatigue, depressive mood, emotional lability, and change in mood.


Q: Do I need to have regular blood tests while taking Aelie?

Official warnings detail the need for monitoring serum potassium in specific high-risk females during the initial cycle of treatment. Blood pressure monitoring during treatment is a common regulatory consideration.


Q: What is the typical timeframe for seeing the full benefits of Aelie?

For contraceptive use, regulatory documents state the drug is not considered effective until after the first seven consecutive days. For other indications, such as Premenstrual Dysphoric Disorder (PMDD), research evidence was not evaluated beyond three menstrual cycles.


Q: What does 'contraindication' mean in relation to Aelie?

A contraindication is an official statement in regulatory documents that indicates a condition or factor that prevents the use of the medicine. The drug is prohibited in this situation because the risk of harm is considered to be too high.


Q: Are there lifestyle changes recommended alongside taking Aelie?

Regulatory documents include a specific restriction that prohibits use in women over age 35 who smoke. This is due to the significantly increased risk of cardiovascular events associated with that combination.


Q: Can Aelie cause skin issues or rashes?

Official documentation lists skin rash, itching, and hives as potential signs of an allergic reaction. Chloasma, which is characterized by dark patches of skin, may also occur.


Q: What are the official recommendations for discontinuing Aelie?

Official warnings describe specific medical circumstances under which the medicine is to be discontinued, such as if a thrombotic event occurs or if pregnancy is confirmed. These circumstances include stopping use four weeks prior to and through two weeks after major surgery.


Q: How quickly does Aelie start to work after taking it?

For contraceptive protection, official drug documents state that the drug is not considered fully effective until after the first seven consecutive days of administration.


Q: If I stop taking Aelie, what happens?

If the use of Aelie is stopped, the protective effects of the medication are lost. Fertility can return shortly after stopping, and withdrawal bleeding usually occurs within a few days of discontinuing the active tablets.


Q: Can Aelie affect a person's sleep patterns?

Official safety documents list 'difficulty in sleeping' as a potential side effect of the medication.


Q: Is Aelie available in a generic version?

Yes, generic versions of the active ingredient combination, Drospirenone and Ethinylestradiol, are available.


Q: What happens if Aelie is taken with alcohol?

The interaction between the Ethinyl Estradiol component and alcohol is classified in drug information systems as a minor drug interaction.


Q: How is Aelie removed from the body?

The Drospirenone component possesses anti-mineralocorticoid activity, which affects the body's salt and water balance. This action promotes sodium excretion as part of the body's process for eliminating the drug's components.


Q: Is Aelie a controlled substance?

According to official sources, the active ingredients, Drospirenone and Ethinylestradiol, are not classified as controlled substances under federal law.


Q: Do official documents mention any potential for dependency with Aelie?

The drug is not listed as a controlled substance in the official drug schedules. This regulatory classification is partly based on a substance's potential for abuse or dependence.


Q: What is the purpose of the long list of warnings in the Aelie patient leaflet?

Warnings and informational sections are included in regulatory documents to ensure patient safety. They are designed to inform both the patient and the prescriber of all known potential risks and severe side effects for appropriate use and safety monitoring.

How should Aelie be stored and disposed of?

As of the current regulatory documentation, a specific drug product named Aelie is not listed in authoritative government drug databases (such as those maintained by the FDA or EMA) with a defined official storage and disposal profile.

Official Regulatory Profile Status

Section Status Based on Official Sources
Labeled Storage Requirements No specific temperature or environmental requirements found.
In-Use Stability / Handling No specific shelf-life or post-reconstitution instructions found.
Disposal Instructions No specific drug-flushing or hazardous waste instructions found.
Child-Protection Storage Universal Requirement: Keep all medicines out of the sight and reach of children.

General Disposal Guidance

In the absence of drug-specific instructions, the U.S. FDA and other global authorities recommend using a drug take-back program (e.g., pharmacy drop-off kiosks, DEA Take-Back Events) as the primary method for discarding unused or expired medicines to ensure proper disposal and environmental safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aelie found in:

A-Z Index: